Fetal behavior and gestational serotonin reuptake inhibitor exposure: relationships between behavior, drug dosage, plasma drug level, and a measure of drug bioeffect.

Autor: Salisbury AL; School of Nursing, Virginia Commonwealth University, Richmond, VA, 23298-0567, USA. salisburya@vcu.edu.; Department of Pediatrics, Women & Infants Hospital, Alpert Medical School at Brown University, Providence, RI, USA. salisburya@vcu.edu., Anderson GM; Child Study Center and the Department of Laboratory Medicine, Yale University School of Medicine, 230 S. Frontage Rd., New Haven, CT, 06525, USA., Yang A; AY Analytics, Chicago, IL, 60611, USA., Stika CS; Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, 676 North St Clair Street, Suite 1000, Chicago, IL, 60611, USA., Rasmussen-Torvik LJ; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, 680 N Lake Shore Drive, Suite 1400, Chicago, IL, 60611, USA., Gollan JK; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, 676 North St Clair Street, Suite 1000, Chicago, IL, 60611, USA., Wisner KL; Children's National Hospital, Developing Brain Institute, 111 Michigan Ave., NW, 20001, Washington, DC, USA.
Jazyk: angličtina
Zdroj: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2024 Dec; Vol. 49 (13), pp. 1968-1977. Date of Electronic Publication: 2024 Aug 10.
DOI: 10.1038/s41386-024-01923-1
Abstrakt: Determination of the relationships between drug dosage, maternal and infant (cord blood) plasma drug concentrations, and serotonin reuptake inhibitor (SRI) bioeffect on offspring neurobehavior is crucial to assessing the effects of gestational SRI exposure. Measurement of maternal and cord blood platelet serotonin (5-HT) provides an index of inhibitory bioeffect at the 5-HT transporter and complements other measures of drug exposure. Three groups of mother-infant pairs were evaluated: (1) mothers with depression untreated with SRIs (DEP, n = 17), (2) mothers treated for depression with SRIs (DEP + SRI, n = 17), and (3) mothers who were not depressed and untreated (ND, n = 29). Fetal movement was assessed using a standardized ultrasound imaging and rating protocol. Maternal and cord blood platelet 5-HT levels were obtained from all participants. For the SRI + DEP group, maternal and infant plasma drug concentrations and an estimate of third-trimester maternal SRI drug exposure were obtained. As expected, substantially lower median platelet 5-HT levels were observed in the DEP + SRI group than in the non-exposed, combined ND and DEP groups. In non-exposed mothers and infants, platelet 5-HT levels were not affected by the presence of maternal depression. Lower maternal and infant platelet 5-HT levels were associated with more immature fetal movement quality. Although these data are limited by small sample size, the bioeffect index of in vivo platelet 5-HT transporter inhibition appears to provide a valuable approach for elucidating and possibly predicting the effects of gestational SRI exposure on fetal and perinatal neurobehavior.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: